Related references
Note: Only part of the references are listed.Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands
Frank D. Verbraak et al.
ACTA OPHTHALMOLOGICA (2021)
Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration: Data from a real-world clinical setting
Corinne Fulcher et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2020)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Macular Atrophy in Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)
Mark C. Gillies et al.
OPHTHALMOLOGY (2020)
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Joao Carrasco et al.
ADVANCES IN THERAPY (2020)
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52-and 96-Week Findings from ALTAIR A Randomized Controlled Trial
Masahito Ohji et al.
ADVANCES IN THERAPY (2020)
Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
Adam H. Ross et al.
EYE (2020)
Off-label use of bevacizumab for wet age-related macular degeneration in Europe
Tomas Bro et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2020)
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease A Randomized Clinical Trial
Peter J. Kertes et al.
JAMA OPHTHALMOLOGY (2020)
Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment
Takeshi Joko et al.
PATIENT PREFERENCE AND ADHERENCE (2020)
Four-Year Outcome of Aflibercept Treatment-Naive Patients for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Yanel Gayadine-Harricham et al.
JOURNAL OF OPHTHALMOLOGY (2020)
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
Kanako Itagaki et al.
BMC OPHTHALMOLOGY (2020)
Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration
Alaa Din Abdin et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2019)
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Michele Augsburger et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2019)
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease
Peter J. Kertes et al.
OPHTHALMOLOGY (2019)
Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes
John F. Payne et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen
Peter G. Traine et al.
OPHTHALMOLOGY RETINA (2019)
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration Results with Ranibizumab from the TREND Study
Rufino Silva et al.
OPHTHALMOLOGY (2018)
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective
Freekje van Asten et al.
PLOS ONE (2018)
TWO YEAR OUTCOMES OF TREAT AND EXTEND INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Daniel Barthelmes et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
Luis Hernandez et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia
Polona Jaki Mekjavic et al.
BMC OPHTHALMOLOGY (2018)
Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study
Katja Hatz et al.
ACTA OPHTHALMOLOGICA (2017)
ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up
Alicia Valverde-Megias et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
Robert L. Johnston et al.
ADVANCES IN THERAPY (2017)
Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model
Pasi Vottonen et al.
ACTA OPHTHALMOLOGICA (2016)
Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden
Hemangi R. Panchmatia et al.
ACTA OPHTHALMOLOGICA (2016)
Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol Two-Year Results
Karina Berg et al.
OPHTHALMOLOGY (2016)
Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
A. M. E. Schauwvlieghe et al.
PLOS ONE (2016)
Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration TREX-AMD 1-Year Results
Charles C. Wykoff et al.
OPHTHALMOLOGY (2015)
Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
Karina Berg et al.
OPHTHALMOLOGY (2015)
Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: A systematic review
Jessica Boyle et al.
PSYCHOLOGY HEALTH & MEDICINE (2015)
The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters
Mari Elshout et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
Helen A. Dakin et al.
BMJ OPEN (2014)
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wan Ling Wong et al.
LANCET GLOBAL HEALTH (2014)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY (2012)
A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS
Margriet I. Van der Reis et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
Share Paper
